Pembrolizumab (Keytruda), an anti-PD-1 antibody, cleared minimal residual disease and protected against recurrence in ...

A new research paper was published in , Volume 16, on April 24, 2025, titled "PD-L1 and FOXP3 expression in high-grade squamous intraepithelial lesions of the anogenital region." ...

The PFS benefit was demonstrated in patients with either PD-L1-positive or PD-L1-negative tumors. Akeso noted that no new safety signals were identified in this Phase III study. The full data set ...